Lipocine Inc LPCN

NAS: LPCN | ISIN: US53630X1046   8/05/2024
4,850 USD (-3,19%)
(-3,19%)   8/05/2024

8 mei 2024 · Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 · Persbericht

1 mei 2024 · Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 · Persbericht

11 april 2024 · Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity · Persbericht

28 maart 2024 · Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis · Persbericht

25 maart 2024 · Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 · Persbericht

7 maart 2024 · Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 · Persbericht

6 maart 2024 · Lipocine to Present at 36th Annual Roth Conference · Persbericht

6 februari 2024 · Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 · Persbericht

2 februari 2024 · Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals · Persbericht

18 januari 2024 · Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada · Persbericht

19 december 2023 · Lipocine to Present at Biotech Showcase 2024 · Persbericht

8 november 2023 · Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 · Persbericht

1 november 2023 · Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023 · Persbericht

26 oktober 2023 · Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression · Persbericht

24 oktober 2023 · Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference · Persbericht

19 september 2023 · Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference · Persbericht

10 augustus 2023 · Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 · Persbericht

27 juli 2023 · LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis · Persbericht

14 juni 2023 · Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference · Persbericht

7 juni 2023 · Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 · Persbericht

Mijn selecties